ABEO – abeona therapeutics inc. (US:NASDAQ)
Stock Stats
News
11/13
12:08 am
abeo
Low
Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/12
01:56 pm
abeo
Low
Abeona Therapeutics gets PDUFA date for its epidermolysis bullosa treatment [Seeking Alpha]
11/12
07:30 am
abeo
Medium
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
11/7
02:07 pm
abeo
Low
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market Evolution - Technavio [Yahoo! Finance]
11/4
07:30 am
abeo
Medium
Abeona Therapeutics® Announces Participation in November Investor Conferences
8/12/2024
07:30 am
abeo
12.2%
BEAT
5/15/2024
07:30 am
abeo
12.4%
MISS
10/31
08:35 am
Reiterates
Buy
Buy
HC Wainwright
Low
0.9%
10/29
12:22 pm
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
3.0%
10/29
11:47 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
1.7%
9/20
11:27 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Medium
3.1%
9/20
11:07 am
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
2.9%
11/12
05:25 pm
abeo
Low
Form DEF 14A ABEONA THERAPEUTICS INC. For: Nov 12
11/12
09:44 am
abeo
Medium
Form 8-K ABEONA THERAPEUTICS INC. For: Nov 08
10/29
07:31 am
abeo
Low
Form 8-K ABEONA THERAPEUTICS INC. For: Oct 28
10/17
04:31 pm
abeo
Low
Form 4 ABEONA THERAPEUTICS INC. For: Oct 16 Filed by: Seshadri Vishwas
10/8
04:30 pm
abeo
Low
Form SC 13G/A ABEONA THERAPEUTICS INC. Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Show more
Top News Gainers
9/3 Abeona Therapeutics Announces Strategic Review 83.8%
3/16 Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates 40.7%
12/10 Abeona Therapeutics Inc (NASDAQ: ABEO) had its "hold" rating re-affirmed by analysts at Mizuho. They now have a $4.00 price target on the stock. 28.6%
10/15 Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa 21.0%
12/10 Form 8-K ABEONA THERAPEUTICS INC. For: Dec 09 20.7%
12/20 Form 25-NSE ABEONA THERAPEUTICS INC. Filed by: The Nasdaq Stock Market LLC 14.2%
2/10 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $6.00 price target on the stock. 11.4%
8/13 Abeona Therapeutics Inc (NASDAQ: ABEO) had its price target lowered by analysts at Royal Bank of Canada to $16.00. They now have a "positive" rating on the stock. 10.3%
2/11 Abeona Therapeutics Inc (NASDAQ: ABEO) is now covered by analysts at Leerink Swann. They set a "buy" rating and a $6.00 price target on the stock. 9.7%
1/21 Abeona Therapeutics Announces Participation in Inaugural World Congress on Epidermolysis Bullosa 9.4%
Top News Decliners
12/19 Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants -37.7%
7/25 Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA -20.0%
6/18 Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease -16.5%
3/17 Form SEC STAFF LETTER ABEONA THERAPEUTICS INC. -15.4%
9/23 Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa -11.9%
8/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating. -11.1%
12/9 Abeo on go with late-stage study of RDEB gene therapy; shares up 3% [Seeking Alpha] -10.4%
10/15 Abeona Therapeutics Inc (NASDAQ: ABEO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.1%
1/13 Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa -9.2%
12/4 Edited Transcript of ABEO earnings conference call or presentation 13-Nov-19 3:00pm GMT [Yahoo! Finance News] -8.6%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3